Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02742779 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

A Phase 1 study of Healthy Volunteer, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
95
Enrollment target
1
Study location

NCT02742779 is a Phase 1 study of Healthy Volunteer that has completed, run by Genentech. The registered enrollment target is 95 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02742779, a Phase 1 study of Healthy Volunteer, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
95 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple orally ascending doses of GDC-0310 administered in healthy participants as 4 parts including Part 1- a single dose (SD) part using a powder-in-capsule (PIC) formulation, Part 2- a multiple dose (MD) part using a PIC formulation, Part 3- a SD part using a solution formulation, and Part 4- a MD part using a solution formulation. Effects of food on pharmacokinetics (PK) will also be explored.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG GDC-0310

Study Locations (1)

Utah

  • PRA Health Sciences - Salt Lake City

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2015-09-15
Est. Completion 2017-06-07
Phase Phase 1

Sponsor

Genentech

332 total trials

What the Registry Record Tells You About NCT02742779

The ClinicalTrials.gov registry entry for NCT02742779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (53% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02742779 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT02742779 about?

NCT02742779 is a clinical study titled "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers". The purpose of this study is to evaluate the safety and tolerability of single and multiple orally ascending doses of GDC-0310 administered in healthy participants as 4 parts including Part 1- a single dose (SD) part using a powder-in-capsule (PIC) formulation, Part 2- a multiple dose (MD) part usin...

What is the current status of trial NCT02742779?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2015-09-15. Estimated completion is 2017-06-07.

What conditions does trial NCT02742779 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT02742779?

The interventions under investigation include: Placebo (DRUG), GDC-0310 (DRUG).

Who is sponsoring clinical trial NCT02742779?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02742779 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.